Market Closed - Euronext Paris 12:35:18 2024-03-28 pm EDT After market 03:51:46 pm
3.637 EUR +1.28% Intraday chart for Valneva 3.63 -0.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate MT
Valneva: Phase 1 trial initiated in the Zika virus CF
Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate CI
ADRs End Higher; XTL Biopharmaceuticals Climbs 129% DJ
Valneva SE Raises Revenue Guidance for 2024 CI
Valneva SE Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Valneva SE, 2023 Earnings Call, Mar 20, 2024
Valneva: share price down, forecasts below expectations CF
French biotech company Valneva raises product sales guidance RE
Valneva: first loan repayment postponed CF
Valneva Secures 18-month Extension to Interest-only Period for US Debt Facility MT
Valneva: the Grimaud family group below 15% of voting rights CF
U.S. CDC Advisory Committee Recommends Use of Valneva?s Single-Dose Chikungunya Vaccine IXCHIQ CI
Valneva: Ixchiq vaccine recommended by ACIP CF
US Centers for Disease Control's Committee Recommends Valneva's Chikungunya Virus Vaccine MT
Valneva SE Announces Revenue Results for Full Year 2023 CI
Valneva Se Announces Earnings Guidance for 2024 CI
Valneva: 26% increase in product sales in 2023 CF
VALNEVA : Oddo BHF confirms its recommendation on the stock CF
Valneva Sells Tropical Disease Priority Review Voucher for $103 Million MT
Valneva Sells Chikungunya Virus Vaccine’s Priority Review Voucher for $103 Million MT
Valneva: sale of priority review warrant for Ixchiq CF
Valneva: Grimaud holds less than 10% of the capital CF
Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva?S Single-Shot Chikungunya Vaccine CI
CAC40: perfectly still, limited movements CF
Chart Valneva
More charts
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva SE has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva SE's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.637 EUR
Average target price
8.95 EUR
Spread / Average Target
+146.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Valneva - Euronext Paris
  4. News Valneva
  5. Valneva's COVID-19 Booster Improves Immunity in Early-Stage Study